Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.65 |
| ▸ | VIPR1 | P32241 | 4/20 | 0.60 |
| ▸ | VIPR2 | P41587 | 6/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.57 |
| ▸ | GLP1R | P43220 | 5/20 | 0.57 |
| ▸ | ECE1 | P42892 | 1/20 | 0.57 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.57 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.56 |
| ▸ | CCKBR | P32239 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30220503 | 0.97 | TFPI (0.66) | TFPIVIPR1VIPR2KEAP1GLP1R | |
| SCHEMBL30974623 | 0.95 | TFPI (0.63) | TFPIVIPR1VIPR2KEAP1GLP1R | |
| SCHEMBL30165222 | 0.93 | TFPI (0.61) | TFPIVIPR1VIPR2KEAP1 | |
| SCHEMBL30658586 | 0.93 | TFPI (0.67) | TFPIVIPR1VIPR2GLP1RECE1 | |
| SCHEMBL29702365 | 0.90 | TFPI (0.78) | TFPIVIPR1VIPR2GLP1R | |
| SCHEMBL29489273 | 0.90 | TFPI (0.73) | TFPIVIPR1VIPR2GLP1RECE1 | |
| SCHEMBL29519384 | 0.90 | TFPI (0.68) | TFPIVIPR1VIPR2GLP1RECE1 | |
| SCHEMBL30176447 | 0.89 | VIPR1 (0.65) | TFPIVIPR1VIPR2GLP1RECE1 | |
| SCHEMBL30629356 | 0.89 | VIPR1 (0.71) | TFPIVIPR1VIPR2KEAP1GLP1R | |
| SCHEMBL30695558 | 0.89 | TFPI (0.78) | TFPIVIPR1VIPR2GLP1RECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240301003-A1 | PLASMIN-RESISTANT PEPTIDES FOR IMPROVED THERAPEUTIC INDEX | NONO INC. (CA) | 2024-09-12 | — | — | US | claimed |
| EP-3757134-B1 | CHLORIDE SALT OF TAT-NR2B9C | NONO INC (CA) | 2024-03-06 | — | — | EP | claimed |
| US-11911438-B2 | Chloride salt of TAT-NR2B9C | NONO INC. (CA) | 2024-02-27 | — | — | US | claimed |
| US-11878044-B2 | Combination therapy for ischemia | NONO INC. (CA) | 2024-01-23 | — | — | US | claimed |
| EP-4274596-A1 | PLASMIN-RESISTANT PEPTIDES FOR IMPROVED THERAPEUTIC INDEX | NoNO Inc. (CA) | 2023-11-15 | — | — | EP | claimed |
| CN-116897051-A | Plasmin peptides for increasing therapeutic index | 诺诺公司 | 2023-10-17 | — | — | CN | claimed |
| US-20230285504-A1 | INHIBITION OF REPERFUSION INJURY WITH A PSD-95 INHIBITOR | NONO INC. (CA) | 2023-09-14 | — | — | US | claimed |
| US-20230139826-A1 | COMBINATION TREATMENT OF STROKE WITH PLASMIN-CLEAVABLE PSD-95 INHIBITOR AND REPERFUSION | NONO INC. (CA) | 2023-05-04 | — | — | US | claimed |
| US-20230055441-A1 | PLASMIN-RESISTANT PEPTIDES FOR TREATING STROKE AND RELATED CONDITIONS | NONO INC. (CA) | 2023-02-23 | — | — | US | claimed |
| EP-2334315-B1 | AGENTS AND METHODS FOR TREATMENT OF PAIN | NONO INC (CA) | 2023-01-18 | — | — | EP | claimed |
| EP-4106818-A1 | INHIBITION OF REPERFUSION INJURY WITH A PSD-95 INHIBITOR | NoNO Inc. (CA) | 2022-12-28 | — | — | EP | claimed |
| EP-4087880-A1 | PLASMIN-RESISTANT PEPTIDES FOR TREATING STROKE AND RELATED CONDITIONS | NoNO Inc. (CA) | 2022-11-16 | — | — | EP | claimed |
| WO-2022150655-A1 | PLASMIN-RESISTANT PEPTIDES FOR IMPROVED THERAPEUTIC INDEX | NONO INC. (CA) | 2022-07-14 | — | — | WO | claimed |
| US-20220175879-A1 | THERAPY FOR SUBARACHNOID HEMORRHAGE AND ISCHEMIA | NONO INC. (CA) | 2022-06-09 | — | — | US | claimed |
| US-20220175880-A1 | CHLORIDE SALT OF TAT-NR2B9C | NONO INC. (CA) | 2022-06-09 | — | — | US | claimed |
| US-20220106362-A1 | SELENIUM-BASED THERAPIES | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2022-04-07 | — | — | US | claimed |
| US-20220096383-A1 | LYOPHILIZED FORMULATION OF TAT-NR2B9C WITH ACETYLATION SCAVENGER | NONO INC. (CA) | 2022-03-31 | — | — | US | claimed |
| US-11266714-B2 | Chloride salt of TAT-NR2B9C | NONO INC. (CA) | 2022-03-08 | — | — | US | claimed |
| EP-3427748-B1 | COMBINATION THERAPY FOR ISCHEMIA | NONO INC (CA) | 2022-03-02 | — | — | EP | claimed |
| CN-114057895-A | Chloride salt of TAT-NR2B9c | 诺诺公司 | 2022-02-18 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11266714-B2 | Chloride salt of TAT-NR2B9C | CHRNA9, SCN9A, GRIN2C | TFPI 1322/4885VIPR1 2502/4885VIPR2 2625/4885 |
| US-20220096383-A1 | LYOPHILIZED FORMULATION OF TAT-NR2B9C WITH ACETYLATION SCAVENGER | TREH, TBCA, GALC | TFPI 827/4885VIPR1 2970/4885VIPR2 3177/4885 |
| US-11911438-B2 | Chloride salt of TAT-NR2B9C | CHRNA9, SCN9A, GRIN2C | TFPI 1322/4885VIPR1 2502/4885VIPR2 2625/4885 |
| US-11878044-B2 | Combination therapy for ischemia | PSD, DAPK2, FABP7 | TFPI 75/4885VIPR1 881/4885VIPR2 556/4885 |
| US-20240301003-A1 | PLASMIN-RESISTANT PEPTIDES FOR IMPROVED THERAPEUTIC INDEX | DAO, DNPEP, DDO | TFPI 175/4885VIPR1 914/4885VIPR2 1367/4885 |
| US-20220175879-A1 | THERAPY FOR SUBARACHNOID HEMORRHAGE AND ISCHEMIA | PSD, FABP7, DAPK2 | TFPI 155/4885VIPR1 1757/4885VIPR2 1293/4885 |
| US-20220175880-A1 | CHLORIDE SALT OF TAT-NR2B9C | CHRNA9, SCN9A, GRIN2C | TFPI 1322/4885VIPR1 2502/4885VIPR2 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.